These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19264832)

  • 1. Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
    Vasile E; Tibaldi C; Falcone A
    Ann Oncol; 2009 Apr; 20(4):790-1. PubMed ID: 19264832
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.
    Lee DH; Kim SW; Suh C; Yoon DH; Yi EJ; Lee JS
    Ann Oncol; 2008 Dec; 19(12):2039-42. PubMed ID: 18644828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
    Passaro A; Alesini D; Pochesci A; Cortesi E
    Anticancer Agents Med Chem; 2014 Jun; 14(5):646-50. PubMed ID: 23140355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
    Shao YY; Shau WY; Lin ZZ; Chen HM; Kuo R; Yang JC; Lai MS
    Eur J Cancer; 2013 Jan; 49(1):106-14. PubMed ID: 22897841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Erlotinib in non-small cell lung cancer].
    Takeda M; Okamoto I
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 9. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
    Garfield DH
    J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].
    Wang Y; Li JL; Wang ZP; Hao XZ; Wang B; Zhang XR; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):780-4. PubMed ID: 23291074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
    Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
    Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 13. [Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
    Kunimasa K; Yoshioka H; Iwasaku M; Nishiyama A; Ubukata S; Ishida T
    Nihon Kokyuki Gakkai Zasshi; 2010 Feb; 48(2):166-71. PubMed ID: 20184251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
    Shao YY; Lin CC; Yang CH
    Discov Med; 2010 Jun; 9(49):538-45. PubMed ID: 20587343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
    Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
    Takeda M; Okamoto I; Fukuoka M; Nakagawa K
    J Clin Oncol; 2010 Jun; 28(17):e273-4. PubMed ID: 20385983
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
    Riely GJ; Kris MG; Zhao B; Akhurst T; Milton DT; Moore E; Tyson L; Pao W; Rizvi NA; Schwartz LH; Miller VA
    Clin Cancer Res; 2007 Sep; 13(17):5150-5. PubMed ID: 17785570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
    Rossi A; La Salvia A; Di Maio M
    Expert Rev Respir Med; 2017 Mar; 11(3):171-180. PubMed ID: 28152323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.